Corporate News Update – 21 October 2026
Zenas Biopharma (ZBIO)
- Trading performance (24 h ending 04:07 PM CET): +5.5 %
- Current share price: USD 28.41
- Shares outstanding: 65.1 million
- Market capitalization: USD 1.7 billion
- Volume (last 24 h): USD 15.5 million
- Month‑end trend: –13.43 % since the previous month‑end
- 200‑day simple moving average: USD 24.56
- 52‑week range: high USD 44.60 (24 Dec 2025); low USD 13.50 (05 Jan 2026)
Related Stocks – 24‑Hour Performance
| Ticker | 24‑h Change | Current Price | Market Cap | Notes |
|---|---|---|---|---|
| AEHR (Aehr Test) | –2.12 % | USD 63.76 | USD 2.1 bn | Director Rhea J. Posedel increased holdings by 18 000 shares at $1.77. File Form 4 dated 20 Oct 2026. Form 8‑K (19 Oct 2026) reports annual meeting results and audit firm ratification. |
| VERA (Vera Therapeutics) | +3.94 % | USD 30.42 | USD 2.1 bn | Two investor webcasts scheduled: 22 Oct 2026 (TRUTAKNA ORIGIN 3 trial data) and 5 Nov 2026 (Q3 2026 results). |
| AXGN (Axogen) | +2.64 % | USD 36.54 | USD 2.1 bn | – |
| VCEL (Vericel) | +0.52 % | USD 40.22 | USD 2.1 bn | P/E ratio: 86.19 |
| AGIO (Agios Pharmaceuticals) | +4.99 % | USD 36.87 | USD 2.1 bn | FDA granted priority review for supplemental mitapivat application in sickle cell disease; Phase 3 RISE UP study showed favorable hemoglobin response. |
Summary
Zenas Biopharma’s shares advanced by 5.5 % in the latest trading session, bringing the price to USD 28.41. The company’s market capitalization remains at USD 1.7 billion with 65.1 million shares outstanding. Trading volume in the last 24 hours was USD 15.5 million, reflecting moderate liquidity. The 200‑day moving average is below the current price, suggesting a bullish short‑term trend. Over the past month, the stock has fallen by 13.43 %, indicating a broader downward movement.
Among peer companies, Aehr Test, Vera Therapeutics, Axogen, Vericel, and Agios Pharmaceuticals all recorded positive intraday gains. Notable corporate actions include Aehr Test’s director share acquisition, Vera Therapeutics’ upcoming investor presentations, and Agios’s FDA priority review for mitapivat in sickle cell disease. These developments may influence sector sentiment and provide context for Zenas Biopharma’s recent performance.
